JAK2 V617F Mouse Pharmacokinetics Analysis: Comprehensive Preclinical PK Study Services

JAK2 V617F mouse pharmacokinetics analysis is a specialized preclinical service designed to evaluate the absorption, distribution, metabolism, and excretion (ADME) profiles of drug candidates in JAK2 V617F mutant mouse models of myeloproliferative neoplasms. This analysis provides critical insights into drug exposure, clearance, and target engagement for JAK inhibitors and other therapeutic candidates. By leveraging validated bioanalytical methods and disease-relevant animal models, researchers can make informed decisions during preclinical drug development.

Technical Overview

The JAK2 V617F gain-of-function mutation is the most prevalent genetic abnormality in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), present in approximately 95% of polycythemia vera patients and 50-60% of patients with essential thrombocythemia and primary myelofibrosis. This somatic mutation within the pseudokinase domain (JH2) of the Janus kinase 2 protein results in constitutive activation of JAK-STAT signaling, driving uncontrolled myeloproliferation. JAK2 V617F knock-in and transgenic mouse models faithfully recapitulate the human disease phenotype, making them invaluable tools for evaluating the pharmacokinetic (PK) behavior of JAK inhibitors and other candidate therapeutics.

Pharmacokinetic analysis in JAK2 V617F mice goes beyond standard rodent PK studies because disease pathology can significantly alter drug disposition. Splenomegaly, extramedullary hematopoiesis, elevated hematocrit, and systemic inflammation characteristic of these models may affect plasma protein binding, hepatic metabolism, and tissue distribution. Conducting PK studies directly in the diseased model provides translationally relevant exposure data that better predicts clinical performance in MPN patients. Our platform combines genetically defined animal models, serial micro-sampling techniques, and sensitive LC-MS/MS bioanalysis to deliver high-quality PK datasets supporting lead optimization and IND-enabling programs.

Testing Samples

Plasma Samples

Plasma is the primary matrix for JAK2 V617F mouse PK studies, collected via serial tail vein or submandibular vein micro-sampling, or terminal cardiac puncture under anesthesia. The typical sampling volume of 20-50 microliters per time point permits full PK profile characterization in individual animals, reducing inter-animal variability and animal usage. Anticoagulants such as heparin or K2-EDTA are selected based on assay compatibility with the downstream bioanalytical method.

Serum Samples

Serum may be utilized for compounds where clotting factors do not interfere with quantification or when paired immunogenicity assessments are planned. Serum collection protocols are validated to ensure analyte stability during the clotting process.

Whole Blood Samples

Whole blood analysis is performed when the pharmacologically relevant concentration includes the cellular compartment, which is particularly pertinent for hematologic diseases where target cells (erythrocytes, platelets, leukocytes) may accumulate drug or harbor pharmacodynamic biomarkers such as phosphorylated STAT3 and phosphorylated STAT5.

Tissue and Organ Samples

Tissue distribution studies quantify drug levels in pharmacologically and toxicologically relevant organs, including spleen, bone marrow, liver, kidney, and brain. Splenic and bone marrow exposures are of special interest in JAK2 V617F models given that these organs are primary sites of extramedullary hematopoiesis and disease activity.

Urine and Feces Samples

Excreta collected from metabolic cages enable mass balance and excretion pathway studies, defining the relative contributions of renal and biliary-fecal elimination routes for the test article.

Testing Items

Our JAK2 V617F mouse pharmacokinetics analysis encompasses a comprehensive suite of quantitative assessments:

• Plasma concentration-time profiles following single and multiple dosing via intravenous, oral, intraperitoneal, or subcutaneous routes
• Key PK parameters: Cmax, Tmax, AUC0-t, AUC0-inf, t1/2, clearance (CL), volume of distribution (Vd), and mean residence time (MRT)
• Bioavailability (F%) determination comparing extravascular and intravenous administration
• Dose proportionality and dose-exposure relationships across escalating dose levels
• Accumulation ratio assessment following repeated dose administration
• Tissue-to-plasma partition coefficients for spleen, bone marrow, and other target organs
• Metabolite identification and profiling to characterize major circulating and excreted metabolites
• Plasma protein binding determination using equilibrium dialysis or ultrafiltration
• Pharmacokinetic-pharmacodynamic (PK/PD) modeling linking exposure to biomarker modulation, including pSTAT3 and pSTAT5 suppression
• Exposure-efficacy correlation with hematocrit normalization, spleen volume reduction, and cytokine level modulation
• Sex- and genotype-dependent differences in drug disposition between mutant mice and wild-type littermate controls

Testing Methods

Study Design and Dosing

Study protocols are customized based on the compound properties and research objectives. Typical designs include single-dose PK, multiple-dose PK, dose escalation, and formulation comparison cohorts. JAK2 V617F homozygous and heterozygous mice, along with matched wild-type controls, are dosed at clinically relevant dose levels, with sampling schemes optimized through pilot studies or physiologically based PK modeling to capture absorption, distribution, and elimination phases.

LC-MS/MS Bioanalysis

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) serves as the primary quantitative platform, offering exceptional sensitivity, specificity, and multiplexing capability. Methods are developed and validated in accordance with FDA and EMA bioanalytical method validation guidance, covering selectivity, accuracy, precision, linearity, recovery, matrix effects, carryover, dilution integrity, and analyte stability in matrix. Calibration curves typically span at least three orders of magnitude to accommodate the wide concentration ranges encountered in tissue and plasma analyses.

Ligand-Binding Assays

For large molecule therapeutics such as monoclonal antibodies targeting JAK2 signaling pathways or accessory targets, validated ELISA and electrochemiluminescence (ECL) platforms are employed, with anti-drug antibody (ADA) screening incorporated into longer-duration studies to interpret unexpected clearance changes.

Pharmacodynamic Biomarker Analysis

PK studies are frequently paired with PD readouts to establish exposure-response relationships. Flow cytometric measurement of phosphorylated STAT3 and phosphorylated STAT5 in whole blood samples, quantitative cytokine panels using multiplex immunoassays, and complete blood count monitoring provide mechanistic confirmation of target engagement alongside the kinetic data.

Data Analysis and Modeling

Concentration-time data are analyzed by non-compartmental analysis (NCA) and, where appropriate, compartmental modeling using validated software. Population PK approaches and PK/PD link models can be constructed to support human dose projection through allometric scaling and model-based translation, facilitating first-in-human dose selection for MPN indications.

Applications

JAK2 V617F mouse pharmacokinetics analysis supports multiple stages of preclinical and translational research:

• Lead optimization of JAK inhibitors, comparing exposure profiles across chemical series to prioritize candidates with favorable half-life and oral bioavailability
• IND-enabling PK package generation, providing formal GLP-compliant or non-GLP toxicokinetic data to support regulatory submissions
• Formulation development and screening, including crystalline versus amorphous forms, particle size optimization, and solubility-enhancing strategies
• Species comparison studies bridging mouse PK data to rat, dog, and non-human primate data for cross-species scaling
• Drug-drug interaction assessment for combination regimens involving JAK inhibitors plus hypomethylating agents, BCL-2 inhibitors, or interferon pathway modulators
• Benchmarking against approved agents such as ruxolitinib and fedratinib to contextualize novel compound performance
• Validation of disease-model influence on drug disposition, quantifying how MPN pathology alters clearance and tissue distribution relative to healthy animals
• Support for gene therapy and targeted delivery programs evaluating novel modalities in the JAK2 V617F disease context

FAQ

Why conduct PK studies in JAK2 V617F mice rather than healthy mice?

Disease physiology in JAK2 V617F mice, including splenomegaly, altered hematocrit, inflammation, and extramedullary hematopoiesis, can meaningfully change drug absorption, distribution, and clearance. PK data generated in the disease model better predicts clinical exposure in MPN patients and allows direct correlation of exposure with efficacy endpoints such as spleen size and blood count normalization.

What sample volumes are required, and can serial sampling be performed?

Serial micro-sampling using 20-50 microliters per time point is standard practice, allowing complete PK profiles from individual mice while respecting animal welfare blood volume limits. This approach reduces the number of animals required and eliminates composite-profile variability.

How long does a typical JAK2 V617F mouse PK study take?

A single-dose PK study including method development, dosing, bioanalysis, and reporting typically completes within 4 to 8 weeks, depending on assay complexity and whether paired PD endpoints are included. Multi-dose and tissue distribution studies may require additional scheduling for steady-state achievement.

Can both plasma PK and pharmacodynamic biomarkers be measured from the same animals?

Yes. Integrated PK/PD study designs routinely combine sparse plasma sampling with pSTAT flow cytometry, cytokine measurements, and hematology assessments, providing coherent exposure-response datasets from the same cohort and improving interpretive power.

Are GLP-compliant study options available?

Non-GLP discovery-stage studies and GLP-compliant toxicokinetic studies following regulatory bioanalytical guidance are both available, allowing seamless progression from early characterization through IND-enabling data packages.

What deliverables are provided at study completion?

Standard deliverables include the study protocol, validated bioanalytical method documentation, individual and mean concentration-time data tables and plots, non-compartmental PK parameter summaries, quality-controlled chromatograms or assay records, and a comprehensive interpretive report with expert commentary on the implications for program advancement.